Plus Therapeutics approves 1-for-25 reverse stock split to meet Nasdaq $1.00 minimum bid price

PLUS THERAPEUTICS, INC.

Reverse split at 1-for-25, effective 12:01 a.m. ET on April 2, 2026; shares drop from ~171.6M to ~6.86M.
Action taken to increase per-share price above Nasdaq's $1.00 minimum bid requirement for continued listing.
No fractional shares issued; cash in lieu; new CUSIP 72941H806; trading symbol stays PSTV.
Broadridge acts as exchange agent; book-entry holders need no action; certificates receive instructions.
Par value unchanged at $0.001; proportional adjustments to equity awards and warrants.

item 3.03 item 5.03 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-140267
form_type: 8-K
ticker: PSTV
cik: 0001095981
company_name: PLUS THERAPEUTICS, INC.
filed_at: 2026-04-02T23:59:59+00:00
discovered_at: 2026-05-14T18:02:31.944751+00:00
generated_at: 2026-05-15T07:47:21.798821+00:00
sec_items: ["3.03", "5.03", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.5
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-140267
json_url: https://secwatch.observer/filing/0001193125-26-140267.json
markdown_url: https://secwatch.observer/filing/0001193125-26-140267.md
text_url: https://secwatch.observer/filing/0001193125-26-140267.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526140267/0001193125-26-140267-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526140267/pstv-20260401.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-140267

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.